Department of Clinical Laboratory Medicine Wakayama Medical University Wakayama.
Department of Clinical Laboratory Medicine Wakayama Medical University Wakayama ; Diabetes Research Institute Fuchu Hospital Osaka Japan.
J Diabetes Investig. 2013 Sep 13;4(5):436-44. doi: 10.1111/jdi.12069. Epub 2013 Mar 18.
AIMS/INTRODUCTION: Islet amyloid polypeptide (IAPP) is a main component of islet amyloid in type 2 diabetes and cosecreted from β-cell with insulin. Clinical evidence from the patients with S20G mutation of the IAPP gene, as well as experimental evidence that insulin could inhibit amyloid formation of IAPP, suggests that a gradual reduction of insulin could be related to the cytotoxicity associated with S20G-IAPP through long-term deterioration of β-cells in type 2 diabetes. Our objective was to show an effect of human insulin on S20G-IAPP associated cytotoxicity.
We analyzed the cytotoxicity associated with S20G-IAPP by controlling human insulin expression using adenovirus vectors with micro ribonucleic acid specifically against human insulin in endocrine AtT-20ins cells, which express human insulin permanently. Additionally, we carried out a follow-up study of circulating IAPP and insulin in type 2 diabetic patients.
S20G-IAPP expression was associated with a decrease in viability and an increase in terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick end labeling-positive cells in AtT-20ins cells. Furthermore, downregulation of human insulin enhanced the cytotoxicity associated with S20G-IAPP, and induced the cytotoxicity associated with wild-type (WT)-IAPP. Reduction of ubiquitin carboxy-terminal hydrolase L1 activity enhanced cytotoxicity under the downregulation of human insulin expression in both S20G- and WT-IAPP transduced cells. A 5-year follow up of type 2 diabetic patients showed a disproportionate increase of serum fasting IAPP-to-insulin ratio from baseline.
Human insulin plays a protective role against the cytotoxicity associated with S20G-IAPP, as well as WT-IAPP. The findings could suggest long-term deterioration of insulin secretion associates with IAPP linked cytotoxicity in type 2 diabetes.
目的/引言:胰岛淀粉样多肽(IAPP)是 2 型糖尿病胰岛淀粉样变的主要成分,与胰岛素一起从β细胞共同分泌。来自 IAPP 基因 S20G 突变患者的临床证据,以及胰岛素可以抑制 IAPP 淀粉样形成的实验证据表明,随着 2 型糖尿病中β细胞的长期恶化,胰岛素的逐渐减少可能与 S20G-IAPP 相关的细胞毒性有关。我们的目的是展示人胰岛素对 S20G-IAPP 相关细胞毒性的影响。
我们通过使用针对人胰岛素的 micro ribonucleic acid 的腺病毒载体来控制人胰岛素的表达,从而分析 S20G-IAPP 相关的细胞毒性,该载体在表达人胰岛素的内分泌 AtT-20ins 细胞中持续表达人胰岛素。此外,我们对 2 型糖尿病患者的循环 IAPP 和胰岛素进行了后续研究。
S20G-IAPP 的表达与 AtT-20ins 细胞活力下降和末端脱氧核苷酸转移酶介导的脱氧尿苷三磷酸生物素 nick 末端标记阳性细胞增加有关。此外,下调人胰岛素增强了 S20G-IAPP 相关的细胞毒性,并诱导了野生型(WT)-IAPP 相关的细胞毒性。下调人胰岛素表达时,泛素羧基末端水解酶 L1 活性的降低增强了 S20G-和 WT-IAPP 转导细胞的细胞毒性。对 2 型糖尿病患者的 5 年随访显示,血清空腹 IAPP 与胰岛素比值从基线开始不成比例地增加。
人胰岛素对 S20G-IAPP 和 WT-IAPP 相关的细胞毒性具有保护作用。这些发现表明,2 型糖尿病中胰岛素分泌的长期恶化与 IAPP 相关的细胞毒性有关。